To the Editor

The COVID-19 pneumonia is a devastating disease without any approved treatment until now [@b0005]. Kirkby and Mackenzie discussed the potential of lungs low dose radiation therapy (LDRT) for COVID-19 pneumonia treatment and suggested the re-examination of this forgotten therapeutic approach [@b0010]. There are tempting reports from the early twentieth century which observed high efficacy of this method to treat pneumonia by X-ray [@b0015], [@b0020]. This may open a new horizon in COVID-19 pneumonia treatment. However, some points should be taken into account to enhance the further clinical trials' outcome.

A comprehensive review of literature exhibited that all the publications about LDRT for pneumonia treatment are too old and haven't been established with satisfactory scientific reliability. Also, considerable limitations and defects in the animal experiments of these publications were observed. Besides, all the human studies were case reports, not reflecting modern randomization of subjects and blinded investigators [@b0025].

The main recommended molecular mechanism by which LDRT treats pneumonia is the induction of anti-inflammatory effects [@b0030]. Thus, the cost and benefit ratio for inhibition of inflammation at COVID-19 patients should be evaluated. Critically ill patients would be the first target for any possible clinical trials. Inflammatory cytokine storm affects a substantial number of these patients [@b0035]. The LDRT is currently used for the decrease of limited inflammations in particular diseases like osteoarthritis and not a cytokine storm [@b0040]. Thus, the anti-inflammatory effect of LDRT may not be very effective in controlling this storm in COVID-19. On the other hand, the most important concern about utilizing anti-inflammatory medications for controlling systemic inflammation is the suppression of immune response against infectious agents [@b0045]. So, LDRT anti-inflammatory effects may disrupt immune system fighting against COVID-19 virus and delay virus elimination. Also, the window time of anti-inflammatory treatment is very important. According to reports, fatal COVID-19 cases are usually fast progressive and deteriorate under two weeks after onset. Therefore, prompt initiation of the anti-inflammatory therapy at this extremely short golden window time is determinative in the treatment outcome [@b0050].

There is limited knowledge about the interaction of LDRT and viruses. Some studies have reported the significant increase of uptake, activation, transcription and spread of some viruses after radiation therapy [@b0055], [@b0060], [@b0065], [@b0070]. Therefore, maybe it's better not to use the lungs as the target organ for radiation therapy due to high virus concentration. It should be mentioned that LDRT anti-inflammatory effects aren't limited to the irradiated site and LDRT exhibits systemic effects [@b0025], [@b0030]. Therefore, maybe it's not necessary to just irradiate the lungs and total body LDRT may exhibit more efficacy.

Overall, it is necessary to completely investigate the LDRT effect on the COVID-19 virus and its cytokine storm in preclinical experiments to balance the risk and benefit ratio before designing further clinical trials. Also, inserting the LDRT anti-inflammatory effects at the right window time for each individual patient is determinative to reach the most favorable outcomes.
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